Evidence map›Paper›PMID 37775552›Full record

ReviewMedical oncology (Northwood, London, England)2023

Solanum nigrum Linn.: Advances in anti-cancer activity and mechanism in digestive system tumors.

Hongyu Pei, Jing Yang, Wang Li, Xing Luo, Yi Xu, Xueying Sun, Qian Chen, Qi Zhao, Li Hou, Gang Tan and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Solamargine inhibited the progression of non-small cell lung cancerEuropean journal of histochemistry : EJH · 2025
    Article
  6. Article
  7. Article
  8. Epigenomics · 2024
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 3 countries.

Hongyu PeiDepartment of Hepatopancreatobiliary Surgery, The Fourth Affiliated Hospital, Harbin Medical University, Harbin, 150001, China.
Jing YangDepartment of Respiratory Medicine, The Fourth Affiliated Hospital, Harbin Medical University, Harbin, China.
Wang LiDepartment of Thyroid and Breast Surgery, The Fourth Affiliated Hospital, Harbin Medical University, Harbin, China.
Xing LuoDepartment of Cardiology, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.
Yi XuDepartment of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin, China.
Xueying SunDepartment of Molecular Medicine & Pathology, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
Qian ChenDepartment of Hepatopancreatobiliary Surgery, The Fourth Affiliated Hospital, Harbin Medical University, Harbin, 150001, China.
Qi ZhaoDepartment of Hepatopancreatobiliary Surgery, The Fourth Affiliated Hospital, Harbin Medical University, Harbin, 150001, China.
Li HouDepartment of Hepatopancreatobiliary Surgery, The Fourth Affiliated Hospital, Harbin Medical University, Harbin, 150001, China.
Gang TanDepartment of Hepatopancreatobiliary Surgery, The Fourth Affiliated Hospital, Harbin Medical University, Harbin, 150001, China. tangang@hrbmu.edu.cn.ORCID http://orcid.org/0000-0001-8096-4798
Daolin JiDepartment of Hepatopancreatobiliary Surgery, The Fourth Affiliated Hospital, Harbin Medical University, Harbin, 150001, China. jidaolin@hrbmu.edu.cn.ORCID http://orcid.org/0000-0001-9029-3801
Harbin Medical University · CNUniversity of Auckland · NZ

Funding

China Postdoctoral Science Foundation 2021M693823Excellent Youth Project of Heilongjiang Natural Science Foundation YQ2022H011Excellent Youth Project of the Fourth Affiliated Hospital of Harbin Medical University HYDSYYXQN202102Heilongjiang Provincial Postdoctoral Science Foundation LBH-Z20180Hong Kong Scholars Program, China XJ2020012National Natural Science Foundation of China 82102911Special Project of the Fourth Affiliated Hospital of Harbin Medical University HYDSYTB201919the Fundamental Research Funds for the Provincial Universities 2021-KYYWF-0259
6 · The paper itself

Abstract

Cancer has currently become a serious public health issue in many countries worldwide, and tumors of the digestive system have attracted an increasing number of researchers' due to their numerous types, high proportion and wide area of occurrence. While tumors of the digestive system suffer from high mortality rates, leading to untimely diagnosis and a poor prognosis, making it necessary to update current treatment approaches such as surgery, radiation therapy, and chemotherapy. This highlights the importance of exploring novel therapeutic ideas and targets. Traditional Chinese medicine has a long history of clinical use due to its low toxicity and multi-factor targeting of multiple pathways. As a kind of traditional Chinese herb, S. nigrum Linn. is highly regarded for its proven antitumor activity. The aim of this study was to comprehensively recapitulate and analyze the anti-cancer effects and molecular mechanisms of treatment of gastrointestinal tumors with S. nigrum Linn. extracts and related compounds, including classical signaling pathways mediated by them as well as noncoding RNA pathways associated with tumor suppression. Components that have been found to be responsible for the anti-cancer activity of S. nigrum Linn. include solanine, solasonine, solamargine, a-L-rhhamnopyranose, uttroside B, degalactotigonin, glycoprotein, and other compounds. The underlying mechanisms of anti-cancer activity reflected in this study include apoptosis, cell cycle arrest, autophagy, anti-angiogenesis, suppression of metastasis and invasion, immune escape, and increased sensitivity to radiotherapy. S. nigrum Linn. has great potential in the treatment of tumors of the digestive system, and through further clinical trials and pharmacological mechanisms it has the potential to become a uniform and standardized anti-tumor drug.

Indexed as

Antineoplastic AgentsAntineoplastic Agents, PhytogenicDigestive System NeoplasmsGastrointestinal NeoplasmsSolanum nigrumHumansPlant ExtractsAntineoplastic AgentsAntineoplastic Agents, PhytogenicPlant ExtractsAnti-cancerApoptosisDigestive system malignant tumorsSolanum nigrum Linn.Traditional Chinese Medicine

Identifiers

PMID37775552
OpenAlexW4387167956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.